Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasis

AIM: Evaluating the preventive efficacy and adjuvant role in therapy of two products containing immunoglobulin Y, ImunoinstantG and Imunoinstant Anti-Candida albicans, in a murine model of vaginal candidiasis. BACKGROUND: Vaginal infections caused by Candida albicans affect approximately 75% of wome...

Full description

Saved in:
Bibliographic Details
Main Authors: Mihai Mares, Andra Cristina Bostanaru Iliescu, Bogdan Minea, Robert Capota, Dana Ciausu Sliwa, Valentin Nastasa
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Journal of Global Antimicrobial Resistance
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213716524003795
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850251806203969536
author Mihai Mares
Andra Cristina Bostanaru Iliescu
Bogdan Minea
Robert Capota
Dana Ciausu Sliwa
Valentin Nastasa
author_facet Mihai Mares
Andra Cristina Bostanaru Iliescu
Bogdan Minea
Robert Capota
Dana Ciausu Sliwa
Valentin Nastasa
author_sort Mihai Mares
collection DOAJ
description AIM: Evaluating the preventive efficacy and adjuvant role in therapy of two products containing immunoglobulin Y, ImunoinstantG and Imunoinstant Anti-Candida albicans, in a murine model of vaginal candidiasis. BACKGROUND: Vaginal infections caused by Candida albicans affect approximately 75% of women, with recurrence involving immune imbalances in 5-8% of cases. METHODS: Thirty female Balb/C mice were equally divided into three groups: Control (C), ImunoinstantG (IG), and Imunoinstant Anti-Candida albicans (IA). Over 22 days, each experimental group received a dose/kg equivalent to an adult human weighing 70 kg (0.9 mg IgY/mouse in 0.35 mL) administered via gavage. The control group received the same volume of drinking water. Both products were administered preventively, starting 7 days before infection. Infection was induced by intravaginally inoculation of 20 µL suspension of Candida albicans wild-type SC5314, containing 2 × 10⁵ CFU. The fungal load (CFU/mL) was assessed in vaginal lavage on days 5, 10, and 15 post-infection. RESULTS: At 15 days post-infection, the fungal load was 2.1 × 10⁴ CFU/mL in group C, 0.4 × 10³ CFU/mL in group IG, and 0.9 × 10² CFU/mL in group IA, respectively. The reduction rate of the fungal load was highest in group IA at all evaluation points, reaching 99.6%. Cytological examination of the lavage fluid indicated a reduced presence of filamentous forms of the yeast and less inflammation for both ImunoinstantG and Imunoinstant Anti-Candida albicans treatments. CONCLUSIONS: These products demonstrated real preventive and therapeutic qualities, based on the significant and gradual reduction in vaginal fungal load throughout the administration period.
format Article
id doaj-art-a83c0dde7e0044b6861847d68e392ca7
institution OA Journals
issn 2213-7165
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Journal of Global Antimicrobial Resistance
spelling doaj-art-a83c0dde7e0044b6861847d68e392ca72025-08-20T01:57:48ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-12-01396310.1016/j.jgar.2024.10.202Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasisMihai Mares0Andra Cristina Bostanaru Iliescu1Bogdan Minea2Robert Capota3Dana Ciausu Sliwa4Valentin Nastasa5Iasi University of Life Sciences, Iasi, RomaniaIasi University of Life Sciences, Iasi, RomaniaGr. T. Popa University of Medicine and Pharmacy, Iasi, RomaniaIasi University of Life Sciences, Iasi, RomaniaIasi University of Life Sciences, Iasi, RomaniaIasi University of Life Sciences, Iasi, RomaniaAIM: Evaluating the preventive efficacy and adjuvant role in therapy of two products containing immunoglobulin Y, ImunoinstantG and Imunoinstant Anti-Candida albicans, in a murine model of vaginal candidiasis. BACKGROUND: Vaginal infections caused by Candida albicans affect approximately 75% of women, with recurrence involving immune imbalances in 5-8% of cases. METHODS: Thirty female Balb/C mice were equally divided into three groups: Control (C), ImunoinstantG (IG), and Imunoinstant Anti-Candida albicans (IA). Over 22 days, each experimental group received a dose/kg equivalent to an adult human weighing 70 kg (0.9 mg IgY/mouse in 0.35 mL) administered via gavage. The control group received the same volume of drinking water. Both products were administered preventively, starting 7 days before infection. Infection was induced by intravaginally inoculation of 20 µL suspension of Candida albicans wild-type SC5314, containing 2 × 10⁵ CFU. The fungal load (CFU/mL) was assessed in vaginal lavage on days 5, 10, and 15 post-infection. RESULTS: At 15 days post-infection, the fungal load was 2.1 × 10⁴ CFU/mL in group C, 0.4 × 10³ CFU/mL in group IG, and 0.9 × 10² CFU/mL in group IA, respectively. The reduction rate of the fungal load was highest in group IA at all evaluation points, reaching 99.6%. Cytological examination of the lavage fluid indicated a reduced presence of filamentous forms of the yeast and less inflammation for both ImunoinstantG and Imunoinstant Anti-Candida albicans treatments. CONCLUSIONS: These products demonstrated real preventive and therapeutic qualities, based on the significant and gradual reduction in vaginal fungal load throughout the administration period.http://www.sciencedirect.com/science/article/pii/S2213716524003795Candida albicansImmunoglobulin Yvaginal candidiasis
spellingShingle Mihai Mares
Andra Cristina Bostanaru Iliescu
Bogdan Minea
Robert Capota
Dana Ciausu Sliwa
Valentin Nastasa
Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasis
Journal of Global Antimicrobial Resistance
Candida albicans
Immunoglobulin Y
vaginal candidiasis
title Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasis
title_full Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasis
title_fullStr Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasis
title_full_unstemmed Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasis
title_short Hyperimmune egg-based IgY-rich formulations as adjuvant therapy in a murine model of vaginal candidiasis
title_sort hyperimmune egg based igy rich formulations as adjuvant therapy in a murine model of vaginal candidiasis
topic Candida albicans
Immunoglobulin Y
vaginal candidiasis
url http://www.sciencedirect.com/science/article/pii/S2213716524003795
work_keys_str_mv AT mihaimares hyperimmuneeggbasedigyrichformulationsasadjuvanttherapyinamurinemodelofvaginalcandidiasis
AT andracristinabostanaruiliescu hyperimmuneeggbasedigyrichformulationsasadjuvanttherapyinamurinemodelofvaginalcandidiasis
AT bogdanminea hyperimmuneeggbasedigyrichformulationsasadjuvanttherapyinamurinemodelofvaginalcandidiasis
AT robertcapota hyperimmuneeggbasedigyrichformulationsasadjuvanttherapyinamurinemodelofvaginalcandidiasis
AT danaciaususliwa hyperimmuneeggbasedigyrichformulationsasadjuvanttherapyinamurinemodelofvaginalcandidiasis
AT valentinnastasa hyperimmuneeggbasedigyrichformulationsasadjuvanttherapyinamurinemodelofvaginalcandidiasis